Advanced search
Publication Cover
Renal Failure Volume 40, 2018 - Issue 1
Submit an article Journal homepage
2,532
Views
8
CrossRef citations to date
0
Altmetric
Clinical Study

Kinetics of carnitine concentration after switching from oral administration to intravenous injection in hemodialysis patients

Anna SuzukiDepartment of Nephrology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan; ;Department of Nephrology, Hakujikai Memorial Hospital, Tokyo, Japan;
,
Yukinao SakaiDepartment of Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanCorrespondence[email protected]
,
Kazumasa HashimotoDepartment of Nephrology, Hakujikai Memorial Hospital, Tokyo, Japan; ;Department of Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
,
Hirokazu OsawaDepartment of Nephrology, Hakujikai Memorial Hospital, Tokyo, Japan;
&
Shuichi TsuruokaDepartment of Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
Pages 196-200 | Received 10 Jun 2017, Accepted 15 Mar 2018, Published online: 04 Apr 2018

References

  • Ozawa H. Nutrition management in severe motor and intellectual disabilities. J Jpn Soc Severe Motor Intellect Disabil. 2012;37:101–106.
  • Stumpf DA, Parker WD Jr, Angelini C. Carnitine deficiency, organic acidemias, and Reye’s syndrome. Neurology. 1985;35:1041–1045.
  • Hurot JM, Cucherat M, Haugh M, et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. JASN. 2002;13: 708–714.
  • Vesela E, Racek J, Trefil L, et al. Effect of L-carnitine supplementation in hemodialysis patients. Nephron. 2001;88:218–223.
  • Savica V, Santoro D, Mazzaglia G, et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Renal Nutr. 2005;15:225–230.
  • Tsushima K, Kase N. Dialysis therapy and carnitine. Methods for the determination of carnitine in human serum. Rinshotoseki. 2000;16:167–173.
  • Maeda K, Shinzato T, Yoshida H, et al. Effects of L-carnitime administration on metabolism of short-chain fatty acid and long-chain fatty acid during hemodialysis. J Jpn Soc Dial Ther. 1987;20:457–463.
  • Kudoh Y, Aoyama S, Torii T, et al. L-carnitine kinetics in chronic hemodialysis patients: comparison between oral and intravenous supplementation. J Biochem Pharmacol Res. 2014;2:117–124.
  • Fukami K, Sakai K, Kaida Y, et al. Effects of oral or intravenous L-carnitine administration on serum carnitine levels and clinical parameters in hemodialysis patients. J Jpn Soc Dial Ther. 2014;47:367–374.
  • Fukami K, Yamagishi S, Sakai K, et al. Effects of switching from oral administration to intravenous injection of L-carnitine on lipid metabolism in hemodialysis patients. Clin Kidney J. 2014;7:470–474.
  • Kolars JC, Watkins PB, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338:1488–1490.
  • Kato Y, Sugiura M, Sugiura T, et al. Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. Mol Pharmacol. 2006;70:829–837.
  • Takeuchi M, Kiyohara M, Machida H, et al. Effects of levocarnitine in hemodialysis patients. J Jpn Soc Dial Ther. 2012;45:955–963.
  • Higuchi T, Abe M, Yamazaki T, et al. Levocarnitine improves cardiac function in hemodialysis patients with left ventricular hypertrophy: a randomized controlled trial. Am J Kidney Dis. 2016;67:260–270.
  • Sakurabayashi T, Miyazaki S, Yuasa Y, et al. L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ J. 2008;72:926–931.
  • Kudoh Y, Aoyama S, Torii T, et al. Hemodynamic stabilizing effects of L-carnitine in chronic hemodialysis patients. Cardiorenal Med. 2013;3:200–207.
  • Ahmad S, Robertson HT, Golper TA, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int. 1990;38:912–918.
  • Wanic-Kossowska M, Kazmierski M, Pawliczak E, et al. Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis. Polskie Archiwum Medycyny Wewnetrznej. 2007;117:14–19.
  • Matsumoto Y, Amano I, Hirose S, et al. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif. 2001;19: 24–32.
  • Trovato GM, Iannetti E, Murgo AM, et al. Body composition and long-term levo-carnitine supplementation. La Clinica Terapeutica. 1998;149:209–214.
  • Duranay M, Akay H, Yilmaz FM, et al. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transpl. 2006;21:3211–3214.
  • Fatouros IG, Douroudos I, Panagoutsos S, et al. Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc. 2010;42:1809–1818.
  • Tabibi H, Hakeshzadeh F, Hedayati M, et al. Effects of l-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: a randomized controlled trial. J Renal Nutr. 2011;21:485–491.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.